Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Merit Ester Cudkowicz, M.D.

Other Positions

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01NS095388 (SMITH, A. GORDON) Jul 1, 2017 - Jun 30, 2021
    Topiramate as a Disease Altering Therapy for CSPN
    Role: Co-Principal Investigator
  2. U44NS090616 (BROWNSTEIN, MICHAEL) Sep 1, 2015 - Aug 31, 2018
    Tolerability of SRX246 in Huntington's Disease Patients
    Role: Co-Principal Investigator
  3. U01NS077179 (CUDKOWICZ, MERIT E) Sep 30, 2011 - Jun 30, 2023
    Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
    Role: Principal Investigator
  4. RC1NS068179 (BOWSER, ROBERT P) Sep 30, 2009 - Aug 31, 2013
    Multi-Center Validation of Biomarkers for Motor Neuron Disease
    Role: Co-Principal Investigator
  5. RC2NS069395 (CUDKOWICZ, MERIT E) Sep 30, 2009 - Aug 31, 2012
    Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Wills AM, Garry J, Hubbard J, Mezoian T, Breen CT, Ortiz-Miller C, Nalipinski P, Sullivan S, Berry JD, Cudkowicz M, Paganoni S, Chan J, Macklin EA. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurol. 2019 May 29; 19(1):104. PMID: 31142272.
  2. Shefner JM, Cudkowicz ME, Hardiman O, Cockroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 May 13; 1-11. PMID: 31081694.
  3. McGarry A, McDermott MP, Kieburtz K, Fung WLA, McCusker E, Peng J, de Blieck EA, Cudkowicz M. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology. 2019 Apr 02; 92(14):e1643-e1651. PMID: 30850442.
  4. Lev MH, Romero JM, Schwamm LH, Cudkowicz ME, Brink JA. Robert H. Ackerman, MD, MPH (1935-2018). AJNR Am J Neuroradiol. 2019 Mar; 40(3):E12-E13. PMID: 30872355.
  5. Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, Di Camillo B, Chio A, Cudkowicz M, Dillenberger D, Garcia-Garcia J, Hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L, Xiao J, Fang WC, Peng J, Yang C, Chang HJ, Stolovitzky G. Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Sci Rep. 2019 Jan 24; 9(1):690. PMID: 30679616.
    Citations:    Fields:    
  6. Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Clarke Haley E, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Mark Haacke E, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann Neurol. 2019 Jan; 85(1):125-136. PMID: 30450637.
    Citations:    Fields:    
  7. Paganoni S, Alshikho MJ, Luppino S, Chan J, Pothier L, Schoenfeld D, Andres PL, Babu S, Zürcher NR, Loggia ML, Barry RL, Luotti S, Nardo G, Trolese MC, Pantalone S, Bendotti C, Bonetto V, De Marchi F, Rosen B, Hooker J, Cudkowicz M, Atassi N. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve. 2019 03; 59(3):303-308. PMID: 30458059.
    Citations:    Fields:    
  8. Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533. PMID: 30564619.
  9. Lin DJ, Cudkowicz ME, Cho TA. Opinion and Special Articles: Challenges and opportunities in defining career identity in academic neurology. Neurology. 2018 Oct 02; 91(14):670-672. PMID: 30275123.
    Citations:    Fields:    
  10. Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 08 30; 379(9):846-855. PMID: 30157388.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  11. Bartlett A, Kolb SJ, Kingsley A, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Coffey CS, Yankey JW, Cudkowicz ME, McGovern MM, McNeil DE, Arnold WD, Kissel JT. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA! Contemp Clin Trials Commun. 2018 Sep; 11:113-119. PMID: 30094386.
  12. McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Comfort N, Wang B, Amacker J, Thankamony S, Salzman DW, Cudkowicz M, Graham DL, Bennett CF, Kordasiewicz HB, Swayze EE, Miller TM. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018 08 01; 128(8):3558-3567. PMID: 30010620.
    Citations: 1     Fields:    
  13. Salter M, Corfield E, Ramadass A, Grand F, Green J, Westra J, Lim CR, Farrimond L, Feneberg E, Scaber J, Thompson A, Ossher L, Turner M, Talbot K, Cudkowicz M, Berry J, Hunter E, Akoulitchev A. Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine. 2018 Jul; 33:169-184. PMID: 29941342.
    Citations: 1     Fields:    Translation:HumansCells
  14. Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018 Jul; 5(4):e465. PMID: 29845093.
  15. Goutman SA, Brown MB, Glass JD, Boulis NM, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges L, Patil PG, Sakowski SA, Feldman EL. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018 Jun; 5(6):730-740. PMID: 29928656.
    Citations: 1     
  16. Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH. Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotroph Lateral Scler Frontotemporal Degener. 2018 08; 19(5-6):331-341. PMID: 29661084.
    Citations: 1     Fields:    
  17. Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 08; 19(5-6):321-330. PMID: 29566571.
    Citations:    Fields:    
  18. Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L, Moreno CAM, Kamalakaran S, Goldstein DB, Gitler AD, Harris T, Myers RM, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018 03 21; 97(6):1268-1283.e6. PMID: 29566793.
    Citations: 3     Fields:    
  19. Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, Joyce NC, Mandeville R, Goyal N, Cudkowicz ME, Weiss M, Miller RG, McDonald CM. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve. 2018 Mar 06. PMID: 29510461.
    Citations:    Fields:    
  20. Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):259-266. PMID: 29402141.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  21. Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018 Feb 13; 90(7):e565-e574. PMID: 29367439.
    Citations: 3     Fields:    
  22. Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):242-249. PMID: 29308669.
    Citations:    Fields:    Translation:Humans
  23. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017 Dec; 82(6):883-891. PMID: 29149772.
    Citations: 11     Fields:    Translation:Humans
  24. Clawson LL, Cudkowicz M, Krivickas L, Brooks BR, Sanjak M, Allred P, Atassi N, Swartz A, Steinhorn G, Uchil A, Riley KM, Yu H, Schoenfeld DA, Maragakis NJ. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):250-258. PMID: 29191052.
    Citations: 2     Fields:    Translation:Humans
  25. Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017 Dec 12; 89(24):2495-2502. PMID: 29142089.
    Citations: 2     Fields:    Translation:Humans
  26. Paganoni S, Alshikho MJ, Zürcher NR, Cernasov P, Babu S, Loggia ML, Chan J, Chonde DB, Garcia DI, Catana C, Mainero C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N. Imaging of glia activation in people with primary lateral sclerosis. Neuroimage Clin. 2018; 17:347-353. PMID: 29159046.
    Citations: 1     Fields:    Translation:HumansCells
  27. Paganoni S, Nicholson K, Chan J, Shui A, Schoenfeld D, Sherman A, Berry J, Cudkowicz M, Atassi N. Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle Nerve. 2018 03; 57(3):430-434. PMID: 28857199.
    Citations:    Fields:    
  28. Paganoni S, Nicholson K, Leigh F, Swoboda K, Chad D, Drake K, Haley K, Cudkowicz M, Berry JD. Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve. 2017 Nov; 56(5):848-858. PMID: 28632945.
    Citations: 2     Fields:    Translation:Humans
  29. Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, Yu H, Wymer J, Cudkowicz M, Macklin EA, Schoenfeld D, Pattee G. Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics. 2017 07; 14(3):830. PMID: 28283968.
    Citations:    Fields:    
  30. Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, Yu H, Wymer J, Cudkowicz M, Macklin EA, Schoenfeld D, Pattee G. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics. 2017 Jul; 14(3):762-772. PMID: 28070747.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  31. Paganoni S, McDonnell E, Schoenfeld D, Yu H, Deng J, Atassi H, Sherman A, Yerramilli-Rao P, Cudkowicz M, Atassi N. Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). J Neurol Neurophysiol. 2017 Apr; 8(2). PMID: 28798889.
    Citations: 1     
  32. Paganoni S, Macklin EA, Karam C, Yu H, Gonterman F, Fetterman KA, Cudkowicz M, Berry J, Wills AM. Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. Muscle Nerve. 2017 Oct; 56(4):726-731. PMID: 28044349.
    Citations: 1     Fields:    Translation:Humans
  33. Andres PL, Allred MP, Stephens HE, Proffitt Bunnell M, Siener C, Macklin EA, Haines T, English RA, Fetterman KA, Kasarskis EJ, Florence J, Simmons Z, Cudkowicz ME. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017 Oct; 56(4):710-715. PMID: 28120413.
    Citations: 1     Fields:    Translation:Humans
  34. Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. J Huntingtons Dis. 2017; 6(2):149-156. PMID: 28671136.
    Citations:    Fields:    Translation:Humans
  35. Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. J Huntingtons Dis. 2017; 6(4):371. PMID: 28922164.
    Citations:    Fields:    
  36. McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159. PMID: 27913695.
    Citations: 9     Fields:    Translation:Humans
  37. Alshikho MJ, Zürcher NR, Loggia ML, Cernasov P, Chonde DB, Izquierdo Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016 Dec 13; 87(24):2554-2561. PMID: 27837005.
    Citations: 12     Fields:    Translation:HumansCells
  38. Lyden P, Weymer S, Coffey C, Cudkowicz M, Berg S, O'Brien S, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Rymer M, Wechsler L, Jadhav A, McNeil E, Waddy S, Pryor K. Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Stroke. 2016 12; 47(12):2979-2985. PMID: 27803392.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  39. Roberts AL, Johnson NJ, Chen JT, Cudkowicz ME, Weisskopf MG. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology. 2016 Nov 29; 87(22):2300-2308. PMID: 27742817.
    Citations: 2     Fields:    Translation:Humans
  40. O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017 02; 18(1-2):120-125. PMID: 27677562.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  41. Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials. 2016 09; 50:166-77. PMID: 27521810.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  42. Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M. Quantitative strength testing in ALS clinical trials. Neurology. 2016 Aug 09; 87(6):617-24. PMID: 27385750.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  43. Cragg JJ, Cudkowicz ME, Weisskopf MG. The Role of Environmental Toxins in Amyotrophic Lateral Sclerosis Risk. JAMA Neurol. 2016 07 01; 73(7):779-80. PMID: 27158795.
    Citations: 1     Fields:    Translation:Humans
  44. Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, Bordeau J, Fournier C, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges LF, Rutkove SB, Duell J, Patil PG, Goutman SA, Feldman EL. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology. 2016 Jul 26; 87(4):392-400. PMID: 27358335.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  45. Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017 Feb; 88(2):99-105. PMID: 27261500.
    Citations: 4     Fields:    Translation:Humans
  46. Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, Cudkowicz M, Atassi N. Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population. J Clin Neuromuscul Dis. 2016 Mar; 17(3):99-105. PMID: 26905909.
    Citations:    Fields:    Translation:Humans
  47. Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016 Apr 19; 86(16):1474-81. PMID: 26911633.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  48. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AH, Bartlett A, Kissel JT. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016 02; 3(2):132-45. PMID: 26900585.
    Citations: 19     
  49. Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, Macklin EA, Schoenfeld D, Cudkowicz M, Sherman A. How common are ALS plateaus and reversals? Neurology. 2016 Mar 01; 86(9):808-12. PMID: 26658909.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  50. Butovsky O, Jedrychowski MP, Cialic R, Murugaiyan G, Wu PM, Doykan CE, Fanek Z, Greco DJ, Kiner O, Lawson RJ, Frosch MP, Pochet N, Krichevsky AM, Gygi SP, Berry J, Cudkowicz ME, Weiner HL. Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. Int J Dev Neurosci. 2015 Dec; 47(Pt A):5. PMID: 26531345.
  51. Butovsky O, Jedrychowski MP, Cialic R, Murugaiyan G, Wu PM, Doykan CE, Fanek Z, Greco DJ, Kiner O, Lawson RJ, Frosch MP, Pochet N, Krichevsky AM, Gygi SP, Berry J, Cudkowicz ME, Weiner HL. REMOVED: Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. Int J Dev Neurosci. 2015 Dec; 47(Pt A):5. PMID: 29887088.
    Citations:    Fields:    
  52. Wainger BJ, Cudkowicz ME. Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis: C9orf72 Repeats. JAMA Neurol. 2015 Nov; 72(11):1235-6. PMID: 26348624.
    Citations: 1     Fields:    Translation:Humans
  53. Weisskopf MG, Cudkowicz ME, Johnson N. Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort. Epidemiology. 2015 Nov; 26(6):831-8. PMID: 26414854.
    Citations: 10     Fields:    Translation:HumansPHPublic Health
  54. Klein MM, Treister R, Raij T, Pascual-Leone A, Park L, Nurmikko T, Lenz F, Lefaucheur JP, Lang M, Hallett M, Fox M, Cudkowicz M, Costello A, Carr DB, Ayache SS, Oaklander AL. Transcranial magnetic stimulation of the brain: guidelines for pain treatment research. Pain. 2015 Sep; 156(9):1601-14. PMID: 25919472.
    Citations: 15     Fields:    Translation:Humans
  55. Paganoni S, Schoenfeld D, Shui A, Cudkowicz M, Miller TM. Reply: To PMID 25900666. Muscle Nerve. 2015 Oct; 52(4):691. PMID: 26138218.
    Citations:    Fields:    Translation:Humans
  56. Roberts AL, Johnson NJ, Cudkowicz ME, Eum KD, Weisskopf MG. Job-related formaldehyde exposure and ALS mortality in the USA. J Neurol Neurosurg Psychiatry. 2016 07; 87(7):786-8. PMID: 26169306.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  57. Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N, Cudkowicz M, Miller TM. Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015 Sep; 52(3):339-43. PMID: 25900666.
    Citations: 2     Fields:    Translation:Humans
  58. Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e100. PMID: 25884010.
    Citations: 10     
  59. Nicholson KA, Cudkowicz ME, Berry JD. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics. 2015 Apr; 12(2):376-83. PMID: 25700798.
    Citations: 4     Fields:    Translation:Humans
  60. Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, Cudkowicz M, Leitner ML. Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? Neurotherapeutics. 2015 Apr; 12(2):417-23. PMID: 25613183.
    Citations: 5     Fields:    Translation:Humans
  61. Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, Hooker JM, Atassi N. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015; 7:409-14. PMID: 25685708.
    Citations: 37     Fields:    Translation:HumansCells
  62. Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME. Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. Toxicol Rep. 2015; 2:1396-1403. PMID: 26705515.
  63. Andrews JA, Paganoni S, Braastad C, Cudkowicz M, Atassi N. Disease burden in upper motor neuron syndromes: a survey of patient perspectives. J Clin Neuromuscul Dis. 2014 Dec; 16(2):104-5. PMID: 25415523.
    Citations: 1     Fields:    Translation:Humans
  64. Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, Lawson RJ, Frosch MP, Pochet N, Fatimy RE, Krichevsky AM, Gygi SP, Lassmann H, Berry J, Cudkowicz ME, Weiner HL. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015 Jan; 77(1):75-99. PMID: 25381879.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  65. Küffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, Li G, Fang L, Mackey L, Hardiman O, Cudkowicz M, Sherman A, Ertaylan G, Grosse-Wentrup M, Hothorn T, van Ligtenberg J, Macke JH, Meyer T, Schölkopf B, Tran L, Vaughan R, Stolovitzky G, Leitner ML. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015 Jan; 33(1):51-7. PMID: 25362243.
    Citations: 36     Fields:    Translation:Humans
  66. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 04; 83(19):1719-25. PMID: 25298304.
    Citations: 29     Fields:    Translation:Humans
  67. Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Nov; 13(11):1083-1091. PMID: 25297012.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  68. Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, Cudkowicz ME, Boeve BF, Dickson D, Floeter MK, Traynor BJ, Morelli C, Ratti A, Silani V, Rademakers R, Brown RH, Rothstein JD, Boylan KB, Petrucelli L, Disney MD. Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron. 2014 Oct 01; 84(1):239. PMID: 28898625.
    Citations: 4     Fields:    
  69. Zhu Y, Fotinos A, Mao LL, Atassi N, Zhou EW, Ahmad S, Guan Y, Berry JD, Cudkowicz ME, Wang X. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov Today. 2015 Jan; 20(1):65-75. PMID: 25205348.
    Citations: 6     Fields:    Translation:HumansAnimals
  70. Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T, Archibald D. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):406-13. PMID: 25125035.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  71. McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshew DA, David W, Cudkowicz M, Glass JD, Appel S, Simpson E, Mitsumoto H. Seeking a measure of clinically meaningful change in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):398-405. PMID: 25124889.
    Citations: 3     Fields:    Translation:Humans
  72. Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, Cudkowicz ME, Boeve BF, Dickson D, Floeter MK, Traynor BJ, Morelli C, Ratti A, Silani V, Rademakers R, Brown RH, Rothstein JD, Boylan KB, Petrucelli L, Disney MD. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014 Sep 03; 83(5):1043-50. PMID: 25132468.
    Citations: 76     Fields:    Translation:HumansAnimalsCells
  73. Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, Cudkowicz M, Atassi N. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):453-6. PMID: 24981792.
    Citations: 14     Fields:    Translation:Humans
  74. Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):362-70. PMID: 24984169.
    Citations: 9     Fields:    Translation:Humans
  75. Meininger V, Pradat PF, Corse A, Al-Sarraj S, Rix Brooks B, Caress JB, Cudkowicz M, Kolb SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J, Krull D, Berges A, Abila B, Meno-Tetang G, Wurthner J. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One. 2014; 9(5):e97803. PMID: 24841795.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  76. Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Harmatz JS, Schoenfeld D, Greenblatt DJ. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J Clin Pharmacol. 2014 Oct; 54(10):1180-7. PMID: 24771634.
    Citations: 4     Fields:    Translation:Humans
  77. Hochberg LR, Cudkowicz ME. Locked in, but not out? Neurology. 2014 May 27; 82(21):1852-3. PMID: 24789868.
    Citations: 2     Fields:    Translation:Humans
  78. Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, Berry JD, Brown RH, Cudkowicz ME, Bean BP, Eggan K, Woolf CJ. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014 Apr 10; 7(1):1-11. PMID: 24703839.
    Citations: 118     Fields:    Translation:HumansCells
  79. Berry JD, Cudkowicz ME, Shefner JM. Predicting success: optimizing phase II ALS trials for the transition to phase III. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar; 15(1-2):1-8. PMID: 24588460.
    Citations: 3     Fields:    Translation:Humans
  80. Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Jun 14; 383(9934):2065-2072. PMID: 24582471.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  81. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103.
    Citations: 44     Fields:    Translation:Humans
  82. Bruijn L, Cudkowicz M. Opportunities for improving therapy development in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun; 15(3-4):169-73. PMID: 24472060.
    Citations: 3     Fields:    Translation:Humans
  83. Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014; 4(7):605-618. PMID: 28203356.
    Citations: 2     
  84. Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013 Nov; 12(11):1059-67. PMID: 24067398.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  85. Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, Deng J, Levine-Weinberg M, Shapiro J, Lee A, Joseph L, Macklin EA, Cudkowicz ME. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013 Oct 08; 81(15):1350-5. PMID: 24005339.
    Citations: 5     Fields:    Translation:Humans
  86. Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec; 14(7-8):632-4. PMID: 23834161.
    Citations: 1     Fields:    Translation:Humans
  87. Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013; 8(4):e61177. PMID: 23613806.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  88. Cohen-Adad J, Zhao W, Keil B, Ratai EM, Triantafyllou C, Lawson R, Dheel C, Wald LL, Rosen BR, Cudkowicz M, Atassi N. 7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis. Muscle Nerve. 2013 May; 47(5):760-2. PMID: 23553571.
    Citations: 6     Fields:    Translation:HumansCells
  89. Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013 May; 12(5):435-42. PMID: 23541756.
    Citations: 121     Fields:    Translation:HumansCTClinical Trials
  90. Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013 Feb; 70(2):201-7. PMID: 23147550.
    Citations: 29     Fields:    Translation:HumansAnimals
  91. Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr; 14(3):162-8. PMID: 23323713.
    Citations: 18     Fields:    Translation:Humans
  92. Gladman M, Cudkowicz M, Zinman L. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Curr Opin Neurol. 2012 Dec; 25(6):735-42. PMID: 23160423.
    Citations: 8     Fields:    Translation:Humans
  93. Andres PL, English R, Mendoza M, Florence J, Malkus E, Schierbecker J, Siener C, Malspeis S, Schoenfeld DA, Munsat TL, Cudkowicz ME. Developing normalized strength scores for neuromuscular research. Muscle Nerve. 2013 Feb; 47(2):177-82. PMID: 23168880.
    Citations: 5     Fields:    Translation:Humans
  94. Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan; 14(1):44-51. PMID: 22985432.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  95. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, Lawson R, Berry J, Krichevsky AM, Cudkowicz ME, Weiner HL. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012 Sep; 122(9):3063-87. PMID: 22863620.
    Citations: 138     Fields:    Translation:HumansAnimalsCells
  96. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8. PMID: 22591195.
    Citations: 13     Fields:    Translation:Humans
  97. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. What does body mass index measure in amyotrophic lateral sclerosis and why should we care? Muscle Nerve. 2012 Apr; 45(4):612. PMID: 22431098.
    Citations: 2     Fields:    Translation:Humans
  98. Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, Kamel F, Nelson LM, Topol B, Van den Eeden SK, Tanner CM, Cudkowicz ME, Grasso DL, Lawson R, Muralidhar S, Oddone EZ, Schmidt S, Hauser MA. A high-density genome-wide association screen of sporadic ALS in US veterans. PLoS One. 2012; 7(3):e32768. PMID: 22470424.
    Citations: 20     Fields:    Translation:Humans
  99. Paganoni S, Zhang M, Quiroz Zárate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012 Sep; 259(9):1923-8. PMID: 22323210.
    Citations: 32     Fields:    Translation:Humans
  100. Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahashi I, Cudkowicz ME. Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs. Int J Toxicol. 2012 Jan-Feb; 31(1):58-69. PMID: 22267890.
    Citations: 1     Fields:    Translation:Animals
  101. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, Cudkowicz M, Glass J, Jahn O, Lehnert S, Malaspina A, Parnetti L, Petzold A, Shaw P, Sherman A, Steinacker P, Süssmuth S, Teunissen C, Tumani H, Wuolikainen A, Ludolph A. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012 Jan; 13(1):1-10. PMID: 22214350.
    Citations: 15     Fields:    Translation:Humans
  102. Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, Cudkowicz ME. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012 Jan; 45(1):81-5. PMID: 22190312.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  103. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012 Jan; 13(1):110-8. PMID: 22117131.
    Citations: 17     Fields:    Translation:Humans
  104. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20; 17(12):1652-6. PMID: 22101764.
    Citations: 33     Fields:    Translation:HumansCells
  105. van Blitterswijk M, Gulati S, Smoot E, Jaffa M, Maher N, Hyman BT, Ivinson AJ, Scherzer CR, Schoenfeld DA, Cudkowicz ME, Brown RH, Bosco DA. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Nov; 12(6):430-8. PMID: 22023190.
    Citations: 5     Fields:    Translation:HumansAnimals
  106. Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond). 2011 Oct; 1(10):1375-1389. PMID: 22545191.
    Citations: 11     
  107. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011 Jul; 44(1):20-4. PMID: 21607987.
    Citations: 54     Fields:    Translation:Humans
  108. Atassi N, Cudkowicz ME, Schoenfeld DA. Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Jul; 12(4):272-7. PMID: 21554030.
    Citations: 5     Fields:    Translation:Humans
  109. Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011 May; 10(5):481-90. PMID: 21511200.
    Citations: 32     Fields:    Translation:HumansAnimals
  110. Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, Cudkowicz M. Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler. 2011 Jan; 12(1):11-6. PMID: 21128868.
    Citations: 5     Fields:    Translation:Humans
  111. Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Mar; 12(2):109-12. PMID: 21091399.
    Citations: 16     Fields:    Translation:Humans
  112. Nefussy B, Hirsch J, Cudkowicz ME, Drory VE. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011 Jan 15; 300(1-2):23-7. PMID: 21056430.
    Citations: 5     Fields:    Translation:Humans
  113. Royce-Nagel G, Cudkowicz M, Myers D, Nicholson K, Shui A, Schoenfeld D, Huang X, Brown RH. Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Oct; 11(5):492-3. PMID: 20438306.
    Citations:    Fields:    Translation:HumansPHPublic Health
  114. Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, Cudkowicz M, Glass JD, Peng J. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J Proteome Res. 2010 Oct 01; 9(10):5133-41. PMID: 20698585.
    Citations: 19     Fields:    Translation:HumansAnimals
  115. Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord. 2010 Sep 15; 25(12):1924-8. PMID: 20669312.
    Citations: 26     Fields:    Translation:Humans
  116. Atassi N, Ratai EM, Greenblatt DJ, Pulley D, Zhao Y, Bombardier J, Wallace S, Eckenrode J, Cudkowicz M, Dibernardo A. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Dec; 11(6):508-13. PMID: 20698808.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  117. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, Lacomis D, Cudkowicz M, Bowser R. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. 2010 Jul; 42(1):104-11. PMID: 20583124.
    Citations: 34     Fields:    Translation:Humans
  118. Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 May 03; 11(3):259-65. PMID: 19961263.
    Citations: 27     Fields:    Translation:Humans
  119. Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 May; 9(5):481-8. PMID: 20363190.
    Citations: 49     Fields:    Translation:Humans
  120. Cudkowicz ME, Swash M. CSF markers in amyotrophic lateral sclerosis: has the time come? Neurology. 2010 Mar 23; 74(12):949-50. PMID: 20308678.
    Citations: 3     Fields:    Translation:Humans
  121. Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010; 11(1-2):178-80. PMID: 19634063.
    Citations: 11     Fields:    Translation:Humans
  122. Lanka V, Wieland S, Barber J, Cudkowicz M. Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs. 2009 Dec; 18(12):1907-18. PMID: 19938902.
    Citations: 14     Fields:    Translation:HumansAnimals
  123. Badayan I, Cudkowicz ME. Profound muscle weakness and pain after one dose of actonel. Case Rep Med. 2009; 2009:693014. PMID: 19826634.
  124. Qureshi M, Bedlack RS, Cudkowicz ME. Lyme disease serology in amyotrophic lateral sclerosis. Muscle Nerve. 2009 Oct; 40(4):626-8. PMID: 19697382.
    Citations: 3     Fields:    Translation:Humans
  125. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009 Oct-Dec; 10(5-6):324-31. PMID: 19922119.
    Citations: 12     Fields:    Translation:Humans
  126. Harel NY, Cudkowicz ME, Brown RH, Strittmatter SM. Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients. Biomarkers. 2009 Sep; 14(6):414-7. PMID: 19548774.
    Citations: 2     Fields:    Translation:Humans
  127. Gordon PH, Corcia P, Lacomblez L, Pochigaeva K, Abitbol JL, Cudkowicz M, Leigh PN, Meininger V. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009 Jun; 66(6):758-61. PMID: 19506136.
    Citations: 11     Fields:    Translation:Humans
  128. Bedlack RS, Silani V, Cudkowicz ME. IPLEX and the telephone game: the difficulty in separating myth from reality on the internet. Amyotroph Lateral Scler. 2009 Jun; 10(3):182-4. PMID: 19110985.
    Citations: 2     Fields:    Translation:Humans
  129. Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009 Apr; 10(2):99-106. PMID: 18688762.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  130. Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, Smith K, Cudkowicz ME, Ferrante RJ. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler. 2009 Apr; 10(2):85-94. PMID: 18618304.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  131. Bedlack RS, Cudkowicz ME. Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance. Front Neurol Neurosci. 2009; 25:144-51. PMID: 19478515.
    Citations: 4     Fields:    
  132. Caraganis A, Benn S, Cudkowicz M, Brown RH. Thrombopoietin is ineffective in a mouse model of motor neuron disease. Amyotroph Lateral Scler. 2008 Dec; 9(6):354-8. PMID: 18608089.
    Citations: 2     Fields:    Translation:Animals
  133. Qureshi M, Shui A, Dibernardo AB, Brown RH, Schoenfeld DA, Cudkowicz ME. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008 Dec; 9(6):369-74. PMID: 18608098.
    Citations: 5     Fields:    Translation:Humans
  134. Badayan I, Cudkowicz ME. Is it too soon for mesenchymal stem cell trials in people with ALS? Amyotroph Lateral Scler. 2008 Dec; 9(6):321-2. PMID: 18819027.
    Citations: 3     Fields:    Translation:HumansAnimals
  135. Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics. 2008 Oct; 5(4):516-27. PMID: 19019302.
    Citations: 17     Fields:    Translation:HumansAnimals
  136. Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz ME. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler. 2008 Oct; 9(5):257-65. PMID: 18608092.
    Citations: 5     Fields:    Translation:Humans
  137. Qureshi M, Brown RH, Rogers JT, Cudkowicz ME. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2008 Sep 12; 2:51-4. PMID: 19452011.
    Citations: 11     
  138. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008 Jul; 38(1):837-44. PMID: 18551622.
    Citations: 34     Fields:    Translation:Humans
  139. Lanka V, Cudkowicz M. Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler. 2008 Jun; 9(3):131-40. PMID: 18574756.
    Citations: 8     Fields:    Translation:HumansAnimals
  140. Meininger V, Shefner J, Cudkowicz M. Lithium therapy in ALS. Amyotroph Lateral Scler. 2008 Apr; 9(2):122. PMID: 18428005.
    Citations: 4     Fields:    Translation:Humans
  141. Wills AM, Landers JE, Zhang H, Richter RJ, Caraganis AJ, Cudkowicz ME, Furlong CE, Brown RH. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology. 2008 Mar 18; 70(12):929-34. PMID: 18347314.
    Citations: 12     Fields:    Translation:HumansCells
  142. Leigh PN, Meininger V, Bensimon G, Cudkowicz M, Robberecht W. Minocycline for patients with ALS. Lancet Neurol. 2008 Feb; 7(2):119-20; author reply 120-1. PMID: 18207106.
    Citations: 9     Fields:    Translation:HumansAnimals
  143. McCormick AL, Brown RH, Cudkowicz ME, Al-Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008 Jan 22; 70(4):278-83. PMID: 18209202.
    Citations: 22     Fields:    Translation:HumansCells
  144. Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler. 2008; 9(1):16-23. PMID: 18273715.
    Citations: 8     Fields:    Translation:Humans
  145. Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH, Cudkowicz M, Gordon PH, Hardy J, Kasarskis EJ, Kaufmann P, Miller R, Sorenson E, Tandan R, Traynor BJ, Nash J, Sherman A, Mailman MD, Ostell J, Bruijn L, Cwik V, Rich SS, Singleton A, Refolo L, Andrews J, Zhang R, Conwit R, Keller MA. Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One. 2007 Dec 05; 2(12):e1254. PMID: 18060051.
    Citations: 5     Fields:    Translation:HumansCells
  146. Rutkove SB, Zhang H, Schoenfeld DA, Raynor EM, Shefner JM, Cudkowicz ME, Chin AB, Aaron R, Shiffman CA. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol. 2007 Nov; 118(11):2413-8. PMID: 17897874.
    Citations: 36     Fields:    Translation:Humans
  147. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007 Aug 21; 69(8):776-84. PMID: 17709710.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  148. Bedlack RS, Traynor BJ, Cudkowicz ME. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May; 12(2):229-52. PMID: 17604499.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  149. Butsch PO, Cudkowicz ME. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis? Exp Neurol. 2007 Jul; 206(1):11-5. PMID: 17498699.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  150. Galpern WR, Cudkowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion. 2007 Jun; 7 Suppl:S146-53. PMID: 17485247.
    Citations: 16     Fields:    Translation:HumansAnimals
  151. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve. 2007 Feb; 35(2):228-34. PMID: 17058270.
    Citations: 6     Fields:    Translation:HumansCells
  152. Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. Neurology. 2007 Jan 02; 68(1):76-7. PMID: 17200499.
    Citations: 5     Fields:    Translation:Humans
  153. Shefner JM, Cudkowicz M, Brown RH. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2006 Nov; 34(5):603-7. PMID: 16892429.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  154. Vucic S, Tian D, Chong PS, Cudkowicz ME, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006 Dec; 129(Pt 12):3384-90. PMID: 17012296.
    Citations: 9     Fields:    Translation:HumansCells
  155. Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, Hilgenberg S, Smart R, Brown RH, Cudkowicz ME. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2006 Sep; 7(3):173-82. PMID: 16963407.
    Citations: 28     Fields:    Translation:Humans
  156. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006 Jul 11; 67(1):20-7. PMID: 16832072.
    Citations: 46     Fields:    Translation:Humans
  157. Lindhorst S, Cudkowicz M. Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? Nat Clin Pract Neurol. 2006 Jul; 2(7):364-5. PMID: 16932586.
    Citations:    Fields:    Translation:Humans
  158. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006 Jul; 60(1):22-31. PMID: 16802291.
    Citations: 84     Fields:    Translation:Humans
  159. Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn. 2006 May; 6(3):387-98. PMID: 16706741.
    Citations: 11     Fields:    Translation:HumansCells
  160. DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochim Biophys Acta. 2006 Nov-Dec; 1762(11-12):1139-49. PMID: 16713196.
    Citations: 8     Fields:    Translation:HumansAnimals
  161. Bruijn LI, Cudkowicz M. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother. 2006 Mar; 6(3):417-28. PMID: 16533145.
    Citations: 5     Fields:    Translation:Humans
  162. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L. Identification of potential CSF biomarkers in ALS. Neurology. 2006 Apr 25; 66(8):1218-22. PMID: 16481598.
    Citations: 59     Fields:    Translation:Humans
  163. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005 Dec 13; 65(11):1834-6. PMID: 16344537.
    Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
  164. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta. 2006 Mar; 1762(3):373-80. PMID: 16364609.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  165. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH, Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. 2005 Dec; 95(5):1461-71. PMID: 16313519.
    Citations: 68     Fields:    Translation:HumansAnimalsCells
  166. Choudry RB, Cudkowicz ME. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. J Clin Pharmacol. 2005 Dec; 45(12):1334-44. PMID: 16291708.
    Citations: 2     Fields:    Translation:HumansAnimals
  167. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH, Ferrante RJ. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005 Jun; 93(5):1087-98. PMID: 15934930.
    Citations: 88     Fields:    Translation:AnimalsCells
  168. Steele AJ, Al-Chalabi A, Ferrante K, Cudkowicz ME, Brown RH, Garson JA. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. 2005 Feb 08; 64(3):454-8. PMID: 15699374.
    Citations: 14     Fields:    Translation:HumansCells
  169. Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of military service and mortality from ALS. Neurology. 2005 Jan 11; 64(1):32-7. PMID: 15642900.
    Citations: 55     Fields:    Translation:Humans
  170. Ascherio A, Weisskopf MG, O'reilly EJ, Jacobs EJ, McCullough ML, Cal